Annual CFO
-$61.27 M
-$29.19 M-91.01%
31 December 2023
Summary:
Enliven Therapeutics annual cash flow from operations is currently -$61.27 million, with the most recent change of -$29.19 million (-91.01%) on 31 December 2023. During the last 3 years, it has fallen by -$52.74 million (-618.36%). ELVN annual CFO is now -618.36% below its all-time high of -$8.53 million, reached on 01 December 2020.ELVN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$12.19 M
+$8.24 M+40.33%
30 September 2024
Summary:
Enliven Therapeutics quarterly cash flow from operations is currently -$12.19 million, with the most recent change of +$8.24 million (+40.33%) on 30 September 2024. Over the past year, it has increased by +$3.70 million (+23.29%). ELVN quarterly CFO is now -89.13% below its all-time high of -$6.45 million, reached on 30 September 2022.ELVN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$68.47 M
+$3.70 M+5.13%
30 September 2024
Summary:
Enliven Therapeutics TTM cash flow from operations is currently -$68.47 million, with the most recent change of +$3.70 million (+5.13%) on 30 September 2024. Over the past year, it has dropped by -$11.54 million (-20.27%). ELVN TTM CFO is now -560.85% below its all-time high of -$10.36 million, reached on 01 March 2022.ELVN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ELVN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -91.0% | +23.3% | -20.3% |
| 3 y3 years | -618.4% | - | - |
| 5 y5 years | - | - | - |
ELVN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -618.4% | at low | -89.1% | +47.8% | -560.9% | +5.1% |
| 5 y | 5 years | -618.4% | at low | -89.1% | +47.8% | -560.9% | +5.1% |
| alltime | all time | -618.4% | at low | -89.1% | +47.8% | -560.9% | +5.1% |
Enliven Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.19 M(-40.3%) | -$68.47 M(-5.1%) |
| June 2024 | - | -$20.43 M(-12.5%) | -$72.17 M(+13.1%) |
| Mar 2024 | - | -$23.36 M(+87.2%) | -$63.79 M(+4.1%) |
| Dec 2023 | -$61.27 M | -$12.48 M(-21.5%) | -$61.27 M(+7.6%) |
| Sept 2023 | - | -$15.89 M(+31.9%) | -$56.93 M(+19.9%) |
| June 2023 | - | -$12.05 M(-42.2%) | -$47.48 M(+11.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$20.84 M(+155.9%) | -$42.56 M(+32.7%) |
| Dec 2022 | -$32.08 M(+67.6%) | -$8.14 M(+26.3%) | -$32.08 M(+34.0%) |
| Sept 2022 | - | -$6.45 M(-9.5%) | -$23.93 M(+36.9%) |
| June 2022 | - | -$7.12 M(-31.2%) | -$17.48 M(+68.8%) |
| Mar 2022 | - | -$10.36 M | -$10.36 M |
| Dec 2021 | -$19.13 M(+124.3%) | - | - |
| Dec 2020 | -$8.53 M | - | - |
FAQ
- What is Enliven Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Enliven Therapeutics?
- What is Enliven Therapeutics annual CFO year-on-year change?
- What is Enliven Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly CFO year-on-year change?
- What is Enliven Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Enliven Therapeutics?
- What is Enliven Therapeutics TTM CFO year-on-year change?
What is Enliven Therapeutics annual cash flow from operations?
The current annual CFO of ELVN is -$61.27 M
What is the all time high annual CFO for Enliven Therapeutics?
Enliven Therapeutics all-time high annual cash flow from operations is -$8.53 M
What is Enliven Therapeutics annual CFO year-on-year change?
Over the past year, ELVN annual cash flow from operations has changed by -$29.19 M (-91.01%)
What is Enliven Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ELVN is -$12.19 M
What is the all time high quarterly CFO for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly cash flow from operations is -$6.45 M
What is Enliven Therapeutics quarterly CFO year-on-year change?
Over the past year, ELVN quarterly cash flow from operations has changed by +$3.70 M (+23.29%)
What is Enliven Therapeutics TTM cash flow from operations?
The current TTM CFO of ELVN is -$68.47 M
What is the all time high TTM CFO for Enliven Therapeutics?
Enliven Therapeutics all-time high TTM cash flow from operations is -$10.36 M
What is Enliven Therapeutics TTM CFO year-on-year change?
Over the past year, ELVN TTM cash flow from operations has changed by -$11.54 M (-20.27%)